FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 478 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Teacher Is Glad She Asked for More Testing After Mammogram Failed... October 28, 2020 Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers February 19, 2025 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 A Systematic Analysis of the Global Burden of Disease from 2010... April 20, 2022 Load more HOT NEWS Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... DeFi Trial: Smart Design and Impressive Results For the Benefit of...
